Analysis Medplus Health Services Limite (MEDPLUS)
5/30/2024
Analysis of Medplus Health Services Limite (MEDPLUS)
Medplus Health Services Limited (MEDPLUS) has shown some volatility in its stock price over the past few days. The RSI indicator has been fluctuating around the 50 level, indicating a balanced market sentiment between buying and selling pressure.The MACD indicator has been positive, suggesting a bullish momentum in the stock. The MACD histogram has also been positive, indicating an increase in bullish momentum.
The moving averages (SMA, EMA, WMA) have been relatively close to each other, indicating a stable trend in the stock price.
Overall, based on the indicators and moving averages, Medplus Health Services Limited seems to be in a relatively stable position with some bullish momentum. However, investors should continue to monitor the stock for any changes in the indicators and moving averages to make informed investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still projected to be positive.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating that there is potential upside according to the analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided yet. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a return on assets of 22.07% and return on equity of 147.25%. The fiscal year ends on September 30, 2023.
Stock statistics reveal a short ratio of 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The company has a market capitalization of $2.92 trillion, with 57.59% held by institutions and 5.22% held by insiders.
Valuation metrics show a PEG ratio of 26.32, forward P/E of 26.32, and trailing P/E of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65.
The stock price summary includes a beta of 1.26, 50-day moving average of $176.26, and 200-day moving average of $181.04. The stock's 52-week low is $164.08, high is $199.62, with a 52-week change of 6.85%.
Dividends and splits information shows a payout ratio of 14.93%, with a forward annual dividend rate of $1 and a trailing annual dividend rate of $0.97. The company had a 4-for-1 split on August 31, 2020, and the last dividend date was on May 16, 2024. The ex-dividend date is May 10, 2024, with a forward annual dividend yield of 0.53% and a 5-year average dividend yield of 0.73%.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, indicating strong operational performance.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with cash and cash equivalents showing fluctuations.
3. Non-current assets consist mainly of investments and advances, with a significant portion in machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown variations, with retained earnings playing a significant role.
6. The company has been utilizing short-term debt and accounts payable for its operations.
7. The provision for risks and charges has been relatively stable over the years.
8. The company has been investing in leases, land, and improvements, indicating a focus on long-term growth.
9. Accumulated depreciation is significant and has been increasing, affecting the value of non-current assets.
10. Overall, the company's financial position seems stable, with a focus on both short-term liquidity and long-term investments.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuuance.
5. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
6. The end cash position has been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next year compared to the previous year's earnings. This indicates potential growth and improvement in the company's financial performance according to analysts' projections.
MACD of MEDPLUS
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
